Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Gastrointestinal 2Breast 2Sarcoma 1Plasma cell 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Melanoma 4Uveal Melanoma 2Rectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Breast Neoplasms 2Brain Neoplasms 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasm Metastasis 1Gliosarcoma 1Glioma 1Glioblastoma 1Ependymoma 1Astrocytoma 1

Interventions

pembrolizumab 16Cyclophosphamide 8Nivolumab 7Gemcitabine 6Paclitaxel 5Drug Therapy 5Docetaxel 5fludarabine 4aldesleukin 4Oxaliplatin 4Fluorouracil 4Carboplatin 4ulixertinib 3spartalizumab 3Trastuzumab 3Radiotherapy 3Leucovorin 3Capecitabine 3trametinib 2tovorafenib 2pertuzumab 2pegilodecakin 2pazopanib 2palbociclib 2osimertinib 2enzalutamide 2cemiplimab 2atezolizumab 2Taxes 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × cediranib × Dermatologic × Clear all
NCT01131234 2014-12-23

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Astrocytoma, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Ependymoma, Glioblastoma, Glioma, Melanoma, Oligodendroglioma, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Gliosarcoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡